Cyclic pyranopterin monophosphate (cPMP) substrate replacement therapy is used to treat a genetic condition called molybdenum cofactor deficiency (MoCD) Type A. It work by replacing missing enzymes in the body to help breakdown toxic compounds. An example is Nulibry (fosdenopterin) that's typically infused through the veins.